Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -


- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the...

Related Keywords

United States , New York , American , Maryc Beckerle , Michaelm Morrissey , Gail Eckhardt , Nasdaq , Share Repurchase Program , Alliance For Clinical Trials In Oncology , Bristol Myers Squibb Company , Exchange Commission , University Of Utah , International Kidney Cancer Symposium , European Society For Medical Oncology , Takeda Pharmaceutical Company , Exelixis Inc , Facebook , Drug Administration , Arcus Biosciences Inc , Huntsman Cancer Institute , National Cancer Institute , American Society Of Clinical Oncology , Translational Research , Extensive Drug Development , Oncological Sciences , College Danl Duncan Comprehensive Cancer Center , Prostate Cancer Clinical Trials Working Group , Chief Executive Officer , Investigational New Drug , Fiscal Year , Ipsen Pharma , Accepted Accounting Principles , Franchise Net Product Revenues , Trial Evaluating Cabozantinib , Advanced Pancreatic , Extra Pancreatic Neuroendocrine Tumors , Medical Oncology , Clinical Trials , Safety Monitoring Board , Metastatic Castration Resistant Prostate Cancer , American Society , Clinical Oncology , Cancers Symposium , Year Follow Up Results , Previously Untreated Renal Cell Carcinoma , Encouraging Results , Expansion Cohort , Evaluating Zanzalintinib , Advanced Kidney Cancer , Arcus Biosciences , Enter Clinical Trial Collaboration , Evaluate Zanzalintinib , Trial Evaluating Zanzalintinib , Previously Untreated Recurrent , Metastatic Head , Provides Strategic Review , Small Molecule Pipeline , Event Calendar , Two New Board Members , Corporate Governance , Exelixis Board , Distinguished Professor , Associate Dean , Experimental Therapeutics , Baylor College , Associate Director , Comprehensive Cancer , Key Priorities , Anticipated Milestones , Abbreviated New Drug Application , Investigational New Drug Applications , Annual Report , Quarterly Reports , Bristol Myers Squibb , Accounting Standards Codification Topic , Markets ,